With the stock's price at Rs 3222.50, Torrent Pharmaceuticals' performance reflects its position in the pharmaceutical sector.

Total revenue from operations grew 7.79% year on year (YoY) to Rs 2,959 crore in the quarter ended 31 March 2025. Profit ...

Shares of ONGC, IndiGo, IndusInd Bank, and RVNL are expected to be in the spotlight today as these companies are set to ...

Indian drugmaker Mankind Pharma reported a fourth-quarter profit that beat analysts' estimates on Wednesday, driven by strong ...

Jefferies recommends Buy on DLF, CMS Info Systems, and Torrent Pharma, citing strong fundamentals and growth prospects. Check ...

Mumbai: Torrent Pharmaceuticals on Wednesday reported a 0.99 per cent quarter-on-quarter (QoQ) decline in its net profit for the fourth quarter (Q4) of FY25, with earnings dropping to Rs 498 crore ...

Torrent Pharmaceuticals posted a steady set of numbers in the fourth quarter, reinforcing confidence in its growth trajectory ...

On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as ...

Net Sales at Rs 2,433.00 crore in March 2025 up 13.53% from Rs. 2,143.00 crore in March 2024. Quarterly Net Profit at Rs. 474.00 crore in March 2025 up 15.61% from Rs. 410.00 crore in March 2024.

Torrent Pharma's US business is set to benefit from new launches and stronger growth momentum, while Germany is likely to see ...